334 / 1082
S319
ESTRO 36 2017
_______________________________________________________________________________________________
treatment.
PO-0618 Role of PET in radiotherapy planning of head
and neck tumors: a systematic review
M. Ferioli
1
, A. Farioli
2
, F. Cellini
3
, A. Arcelli
1,4
, I.
Sandler
5
, S. Cilla
6
, F. Deodato
7
, G. Macchia
7
, S.
Cammelli
1
, A. Guido
1
, F. Romani
8
, A. Angelini
8
, G.
Compagnone
8
, F. Miccichè
3
, R. Frakulli
1
, M. Buwenge
1
, M.
Marengo
8
, V. Valentini
3
, S. Fanti
5
, A.G. Morganti
1
1
University of Bologna, Radiation Oncology Center- Dept.
of Experimental- Diagnostic and Specialty Medicine –
DIMES, Bologna, Italy
2
S. Orsola-Malpighi Hospital- University of Bologna,
Department of Medical and Surgical Sciences DIMEC,
Bologna, Italy
3
Policlinico Universitario “A. Gemelli”- Catholic
University of Sacred Heart, Department of Radiotherapy,
Rome, Italy
4
Ospedale Bellaria, Radiotherapy Department, Bologna,
Italy
5
S. Orsola-Malpighi Hospital- University of Bologna,
Department of Nuclear Medicine, Bologna, Italy
6
Fondazione di Ricerca e Cura “Giovanni Paolo II”-
Catholic University of Sacred Heart, Medical Physics
Unit, Campobasso, Italy
7
Fondazione di Ricerca e Cura “Giovanni Paolo II”-
Catholic University of Sacred Heart, Radiotherapy Unit,
Campobasso, Italy
8
S'Orsola-Malpighi Hospital, Medical Physics Unit,
Bologna, Italy
Purpose or Objective
Use of PET imaging has been proposed in radiotherapy (RT)
treatment planning of locally advanced H&N tumors. Some
studies showed that most local relapses occur in PET-
positive volumes before RT. Therefore, the possibility to
define the GTV using PET-imaging has been considered as
an opportunity to reduce the irradiated volume allowing
Organs at Risk sparing and thus dose-escalation. Some
studies analyzed the volumetric differences between the
GTV volume evaluated by CT versus PET imaging. Aim of
this analysis was to systematically review the available
literature on this issue.
Material and Methods
From Pubmed database, a literature search ('PET” AND
'Radiotherapy Planning”) was performed using the PRISMA
guidelines including published studies about GTV
definition in H&N tumors using CT versus PET imaging.
Reviews, editorials, letters and case reports were
excluded. Only article published in English were
considered.
Results
A total of 14 studies reporting data on GTV definition using
both CT and PET imaging met the inclusion criteria. The
median number of analyzed patients was 26 (range: 6-91).
Eight studies included only patients with SCC H&N tumors.
PET based GTV delineation was performed by manual
contouring (visual method: VM) in 8 studies and by auto-
contouring (AC) using 40-50% intensity level for
18F
-FDG
PET images in 4 studies. Seven studies reported PET-based
GTV-T (primary tumor only), compared to CT-based GTV-
T, being larger in 2 studies (1VM, 1 AC), smaller in 3
studies (3 VM), and not different in 2 studies (1 VM, 1 AC).
Six studies reported PET-based GTV-N (nodal disease
only), compared to CT-based GTV-N, being larger in 1
study (1VM), smaller in 1 study (1 AC), and not different
in 4 studies (3 VM, 1 AC). Seven studies reported PET-
based GTV-T+N (combined primary tumor plus nodal
disease), compared to CT-based GTV-T+N, being smaller
in 5 studies (4 VM, 1 AC) and not different in 2 studies (1
VM, 1 AC). In the evaluation of GTV-T+N, PET-based GTV
showed a significant reduction in 1/2 AC study and in 4/5
VM studies.
Conclusion
Data about the impact of PET imaging in GTV definition in
H&N cancers are conflicting although most studies
evaluating both tumor and nodes GTV showed a reduced
volume using PET. The used PET-delineation methodology
seems to influence the results with larger differences
(compared to CT-scan) by using VM.
PO-0619 Comparison of a nanoString and RNA
microarray gene signature predicting LRC after PORT-C
in HNSCC
S. Schmidt
1,2,3,4
, A. Linge
1,3,4,5,6
, A. Zwanenburg
1,3
, S.
Leger
1,3
, F. Lohaus
1,3,5,6
, V. Gudziol
7
, A. Nowak
8
, I.
Tinhofer
9,10
, V. Budach
9,10
, A. Sak
11,12
, M. Stuschke
11,12
, P.
Balermpas
13,14
, C. Rödel
13,14
, A.L. Grosu
15,16
, A.
Abdollahi
17,18,19,20,21
, J. Debus
17,18,19,20,22
, C. Belka
23,24
, S.E.
Combs
23,25
, D. Mönnich
26,27
, D. Zips
26,27
, G.B.
Baretton
3,28,29
, F. Buchholz
3,30
, M. Baumann
1,2,3,5,6
, M.
Krause
1,2,3,5,6
, S. Löck
1,3,5
1
OncoRay – National Center for Radiation Research in
Oncology, TU Dresden- Med. Faculty Carl Gustav Carus,
Dresden, Germany
2
Helmholtz-Zentrum Dresden – Rossendorf, Institute of
Radiooncology, Dresden, Germany
3
German Cancer Research Center - Heidelberg, DKTK
partner site Dresden, Dresden, Germany
5
National Center for Tumor Diseases NCT, partner site
Dresden, Dresden, Germany
6
TU Dresden - Med. Faculty Carl Gustav Carus,
Department of Radiation Oncology, Dresden, Germany
7
TU Dresden - Med. Faculty Carl Gustav Carus,
Department of Otorhinolaryngology, Dresden, Germany
8
TU Dresden - Med. Faculty Carl Gustav Carus,
Department of Oral and Maxillofacial Surgery, Dresden,
Germany
9
German Cancer Research Center - Heidelberg, DKTK
partner site Berlin, Berlin, Germany
10
Charité University Hospital, Department of
Radiooncology and Radiotherapy, Berlin, Germany
11
German Cancer Research Center - Heidelberg, DKTK
partner site Essen, Essen, Germany
12
Medical Faculty- University of Duisburg-Essen,
Department of Radiotherapy, Essen, Germany
13
German Cancer Research Center - Heidelberg, DKTK
partner site Frankfurt, Frankfurt, Germany
14
Goethe-University Frankfurt, Department of
Radiotherapy and Oncology, Frankfurt, Germany
15
German Cancer Research Center - Heidelberg, DKTK
partner site Freiburg, Freiburg, Germany
16
University of Freiburg, Department of Radiation
Oncology, Freiburg, Germany
17
German Cancer Research Center - Heidelberg, DKTK
partner site Heidelberg, Heidelberg, Germany
18
Heidelberg Institute of Radiation Oncology HIRO-
National Center for Radiation Research in Oncology
NCRO, University of Heidelberg Medical School and
German Cancer Research Center DKFZ, Heidelberg,
Germany
19
Heidelberg Ion Therapy Center HIT, Department of
Radiation Oncology- University of Heidelberg Medical
School, Heidelberg, Germany
20
National Center for Tumor Diseases NCT, partner site
Heidelberg, Heidelberg, Germany
21
University of Heidelberg Medical School and German
Cancer Research Center DKFZ, Translational Radiation
Oncology, Heidelberg, Germany
22
Clinical Cooperation Unit Radiation Oncology,
University of Heidelberg Medical School and German
Cancer Research Center DKFZ, Heidelberg, Germany
23
German Cancer Research Center - Heidelberg, DKTK
partner site Munich, Munich, Germany
24
Ludwig-Maximilians-Universität, Department of
Radiotherapy and Radiation Oncology, Munich, Germany
25
Technische Universität München, Department of
Radiation Oncology, Munich, Germany
26
German Cancer Research Center - Heidelberg, DKTK